Broadcom named strategic vendor for Walmart virtualization solutions
In recent transactions disclosed by UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company with a market capitalization of $325 million, Chief Medical (TASE:BLWV) Officer Mark Schoenberg sold 5,162 ordinary shares, valued at approximately $38,043, on June 9, 2025. These shares were sold at a price of $7.37 each. According to InvestingPro data, the stock has shown significant momentum with a 43% return over the past week, despite trading well below its 52-week high of $20.70. This sale follows the acquisition of 10,000 ordinary shares on June 8, 2025, through the exercise of restricted stock units (RSUs), which were acquired at no cost. The RSUs were part of a grant initially made on June 8, 2023, and are set to vest in three equal annual installments starting June 8, 2024. Following these transactions, Schoenberg’s direct ownership amounts to 153,378 shares. The company maintains impressive gross profit margins of nearly 90% and holds more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights about URGN’s financial health and growth prospects through the comprehensive Pro Research Report.
In other recent news, UroGen Pharma has announced promising results from its ENVISION and ATLAS studies, which were presented at the American Society of Clinical Oncology Annual Meeting. These studies focus on UGN-102, a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and highlight an 18-month duration of response following treatment. The FDA has accepted UroGen’s new drug application for UGN-102, with a decision expected by June 13, 2025. Meanwhile, Oppenheimer has adjusted its price target for UroGen Pharma to $10, down from $36, while maintaining an Outperform rating. This adjustment reflects a revised financial model as the company approaches its PDUFA date. On the other hand, Goldman Sachs has significantly lowered its price target from $16 to $3, citing skepticism from the recent FDA advisory committee vote on UGN-102’s benefit-risk profile. The Oncologic Drugs Advisory Committee’s narrow vote against UGN-102 has raised concerns about its approval prospects. Despite these challenges, UroGen remains committed to working with the FDA to advance the drug’s application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.